Abstract
Background: Mutations in the Fe-S cluster-containing SDHB subunit of succinate dehydrogenase cause familial cancer syndromes. Recently the tripeptide motif L(I)YR was identified in the Fe-S recipient protein SDHB, to which the cochaperone HSC20 binds. Methods: In order to characterize the metabolic basis of SDH-deficient cancers we performed stable isotope-resolved metabolomics in a novel SDHB-deficient renal cell carcinoma cell line and conducted bioinformatics and biochemical screening to analyze Fe-S cluster acquisition and assembly of SDH in the presence of other cancer-causing SDHB mutations. Results: We found that the SDHBR46Q mutation in UOK269 cells disrupted binding of HSC20, causing rapid degradation of SDHB. In the absence of SDHB, respiration was undetectable in UOK269 cells, succinate was elevated to 351.4±63.2 nmol/mg cellular protein, and glutamine became the main source of TCA cycle metabolites through reductive carboxylation. Furthermore, HIF1α, but not HIF2α, increased markedly and the cells showed a strong DNA CpG island methylator phenotype (CIMP). Biochemical and bioinformatic screening revealed that 37% of disease-causing missense mutations in SDHB were located in either the L(I)YR Fe-S transfer motifs or in the 11 Fe-S cluster-ligating cysteines. Conclusions: These findings provide a conceptual framework for understanding how particular mutations disproportionately cause the loss of SDH activity, resulting in accumulation of succinate and metabolic remodeling in SDHB cancer syndromes.
| Original language | English |
|---|---|
| Article number | djv287 |
| Journal | Journal of the National Cancer Institute |
| Volume | 108 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2016 |
Bibliographical note
Publisher Copyright:© 2015 Published by Oxford University Press.
Funding
This research was supported by the Intramural Research Programs of the National Cancer Institute, Center for Cancer Research, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, as well as through a National Institutes of Health (NIH) Bench-to-Bedside award made possible by the NIH Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), NIH Office of Intramural Research, and NIH grants 5R01ES022191, 3R01ES022191-04S1, and 1U24DK097215-01A1.
| Funders | Funder number |
|---|---|
| Center for Cancer Research | |
| NIH Office of Rare Diseases Research | |
| ORDR | |
| National Institutes of Health (NIH) | |
| National Childhood Cancer Registry – National Cancer Institute | P30CA177558 |
| National Childhood Cancer Registry – National Cancer Institute | |
| National Center for Advancing Translational Sciences (NCATS) | U24DK097215, R01ES022191 |
| National Center for Advancing Translational Sciences (NCATS) | |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development |
ASJC Scopus subject areas
- Oncology
- Cancer Research